Protein-losing enteropathy after the Fontan operation: An international multicenter study,☆☆,,★★

https://doi.org/10.1016/S0022-5223(98)70406-4Get rights and content
Under an Elsevier user license
open archive

Abstract

Objective: This multicenter study retrospectively analyzes the data on 114 patients with protein-losing enteropathy after Fontan-type surgery. Special attention was given to the different treatment strategies used and their effect on outcome. Methods and results: In 35 participating centers 3029 Fontan operations were performed. The incidence of protein-losing enteropathy in the survivors was 3.7%. The median age at Fontan-type surgery was 8.2 years (range: 0.6 to 32.9 years). Median age at diagnosis of protein-losing enteropathy was 11.7 years with a median time interval between surgery and diagnosis of 2.7 years (range: 0.1 to 16.4 years). Most patients had edema (79%) and effusions (75%). Hemodynamic data revealed a mean right atrial pressure of 17 ± SD 5.3 mm Hg with a cardiac index of 2.4 ± 0.8 L/min/m2. Medical treatment only (n = 52) resulted in a complete resolution of symptoms in 25%, no improvement in 29%, and death in 46%. Surgical treatment (n = 52) was associated with relief of protein-losing enteropathy in 19%, no improvement in 19%, and death in 62%. In 13 patients 16 percutaneous interventions were performed. This resulted in symptomatic improvement after 12 interventions and no improvement after 4 interventions. Conclusions: We conclude that the current treatment of protein-losing enteropathy after Fontan operation is associated with a very high mortality and morbidity rate. Preventive strategies and new therapeutic approaches are necessary. (J Thorac Cardiovasc Surg 1998;115:1063-73)

Cited by (0)

Sponsored in part by The Belgian Foundation for Research in Pediatric Cardiology.

☆☆

From the Department of Pediatric Cardiology, UZ Leuven, Leuven, Belgiuma; the Department of Pediatric Cardiology, Mayo Clinic, Rochester, Minn.b; Deutsches Herzzentrum, München, Germanyc; and Grown Up Congenital Heart Unit, Royal Brompton and National Heart Hospital, London, United Kingdom.d

Address for reprints: Marc Gewillig, MD, Pediatric Cardiology, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium.

★★

On behalf of the PLE study group